Regression of human prostate tumors and metastases in nude mice following treatment with the recombinant oncolytic vaccinia virus GLV-1h68.
Virotherapy using oncolytic vaccinia virus strains is one of the most promising new strategies for cancer therapy. In the current study, we analyzed the therapeutic efficacy of the oncolytic vaccinia virus GLV-1h68 against two human prostate cancer cell lines DU-145 and PC-3 in cell culture and in tumor xenograft models. By viral proliferation assays and cell survival tests, we demonstrated that GLV-1h68 was able to infect, replicate in, and lyse these prostate cancer cells in culture. In DU-145 and PC-3 tumor xenograft models, a single intravenous injection with GLV-1h68 resulted in a significant reduction of primary tumor size. In addition, the GLV-1h68-infection led to strong inflammatory and oncolytic effects resulting in drastic reduction of regional lymph nodes with PC-3 metastases. Our data documented that the GLV-1h68 virus has a great potential for treatment of human prostate carcinoma.
Gentschev
Ivaylo
I
Genelux Corporation, San Diego Science Center, San Diego, CA 92109, USA.
Donat
Ulrike
U
Hofmann
Elisabeth
E
Weibel
Stephanie
S
Adelfinger
Marion
M
Raab
Viktoria
V
Heisig
Martin
M
Chen
Nanhai
N
Yu
Yong A
YA
Stritzker
Jochen
J
Szalay
Aladar A
AA
D000818:Animals; D000951:Antigens, Neoplasm / Q000378:metabolism; D016923:Cell Death; D045744:Cell Line, Tumor; D000949:Histocompatibility Antigens Class II / Q000276:immunology; D006801:Humans; D008207:Lymphatic Metastasis / Q000473:pathology; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology; D008297:Male; D051379:Mice; D008819:Mice, Nude; D009363:Neoplasm Proteins / Q000378:metabolism; D050130:Oncolytic Virotherapy / Q000379:methods*; D050504:Oncolytic Viruses / Q000502:physiology*; D011471:Prostatic Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy* / Q000821:virology*; D011995:Recombination, Genetic / Q000235:genetics*; D012074:Remission Induction; D014616:Vaccinia virus / Q000502:physiology*; D014779:Virus Replication / Q000502:physiology; D023041:Xenograft Model Antitumor Assays
D000951:Antigens, Neoplasm; D000949:Histocompatibility Antigens Class II; D009363:Neoplasm Proteins